Figure 1

Bevacizumab resulted in tumor regression of a cervical cord hemangioblastoma. This is a sagittal and axial magnetic resonance imaging view of the cervical spine, post gadolinium-diethylene triamine pentaacetic acid administration. Figure 1A (sagittal) and 1D (axial) demonstrate the pre-bevacizumab baseline scan. Figure 1B (sagittal) and 1E (axial) demonstrate tumor regression following two cycles of bevacizumab. Figure 1C (sagittal) and 1F (axial) demonstrate further reduction in the enhancing tumor following an additional four cycles of bevacizumab.